EQL Pharma AB Income Statement

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	425.75	373.52	264.17	259.91	409.75	179.14
Revenue	425.75	373.52	264.17	259.91	409.75	179.14
Revenue Growth (YoY)	25.81%	41.39%	1.64%	-36.57%	128.73%	148.70%
Cost of Revenue	250.39	217.56	149.12	144.06	314.02	128.14
Gross Profit	175.36	155.95	115.05	115.85	95.73	51.01
Selling, General & Admin	97.8	78.46	70.8	59.79	48.16	28.3
Research & Development	13.66	11.26	12.09	15.14	9.13	11.7
Other Operating Expenses	-2.65	-1.14	-0.46	-0.41	-0.4	-0.51
Operating Expenses	108.82	88.58	82.43	74.51	56.9	39.48
Operating Income	66.55	67.37	32.62	41.34	38.84	11.52
Interest Expense	-28.87	-12.34	-5.73	-2.37	-2.87	-1.1
Interest & Investment Income	0.01	0.01	0.2	0	-	-
Other Non Operating Income (Expenses)	-0.68	-0.68	-0	-	0	-
EBT Excluding Unusual Items	37	54.36	27.08	38.97	35.97	10.42
Gain (Loss) on Sale of Investments	-	-	1.53	-	-	-
Pretax Income	37	54.36	28.6	38.97	35.97	10.42
Income Tax Expense	7.66	11.23	5.9	8.05	4.42	0.06
Net Income	29.34	43.12	22.71	30.92	31.55	10.37
Net Income to Common	29.34	43.12	22.71	30.92	31.55	10.37
Net Income Growth	-15.51%	89.93%	-26.57%	-1.99%	204.32%	282.97%
Shares Outstanding (Basic)	29	29	29	29	29	29
Shares Outstanding (Diluted)	30	30	30	30	29	29
Shares Change (YoY)	0.22%	0.34%	0.91%	1.59%	-	-3.37%
EPS (Basic)	1.00	1.48	0.78	1.06	1.09	0.36
EPS (Diluted)	0.98	1.44	0.76	1.04	1.09	0.36
EPS Growth	-15.58%	89.47%	-26.92%	-4.19%	204.32%	296.33%
Free Cash Flow	-12.5	-30.78	-12.36	27.16	41.2	59.64
Free Cash Flow Per Share	-0.42	-1.03	-0.41	0.92	1.42	2.05
Gross Margin	41.19%	41.75%	43.55%	44.57%	23.36%	28.47%
Operating Margin	15.63%	18.04%	12.35%	15.90%	9.48%	6.43%
Profit Margin	6.89%	11.54%	8.60%	11.90%	7.70%	5.79%
Free Cash Flow Margin	-2.94%	-8.24%	-4.68%	10.45%	10.05%	33.29%
EBITDA	85.36	75.68	38.81	47.37	40.54	16.57
EBITDA Margin	20.05%	20.26%	14.69%	18.23%	9.89%	9.25%
D&A For EBITDA	18.81	8.31	6.19	6.03	1.7	5.05
EBIT	66.55	67.37	32.62	41.34	38.84	11.52
EBIT Margin	15.63%	18.04%	12.35%	15.90%	9.48%	6.43%
Effective Tax Rate	20.70%	20.66%	20.62%	20.65%	12.28%	0.53%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.